Patent US4012498A successfully refreshed from Google Patents.
US4012498A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release tablet formulations
Assignee: Sandoz Inc
•
Filing: 1976-02-19
•
Granted: 1977-03-15
•
Expires: 1996-02-19
Abstract
Abstract This invention provides controlled, e.g., sustained release of drugs from medicament formulations containing a plurality of medicaments, wherein a desirable release pattern is maintained for both low concentration and high concentration drugs of the formulation.
Inventors
- 👤 Saul S. Kornblum
- 👤 Samuel B. Stoopak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 08:55
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2072; A61K9/2077
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
83 words
A three component sustained release medicament formulation comprising; a first component comprising phenobarbital and belladonna levoratory alkaloids incorporated into an immediate release portion; a second component comprising belladonna levoratory alkaloids incorporated into a separate basic pH affected controlled release matrix; with phenobarbital, microcrystalline cellulose, and calcium sulfate also incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer resin matrix; and a third component comprising phenobarbital and belladonna levoratory alkaloids each incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer resin matrix.
Claim 2
Dependent Claim
83 words
A three component sustained release medicament formulation comprising; a first component comprising phenobarbital and belladonna levoratory alkaloids incorporated into an immediate release portion; a second component comprising belladonna levoratory alkaloids incorporated into a separate basic pH affected controlled release matrix; with phenobarbital, microcrystalline cellulose, and calcium sulfate also incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer resin matrix; and a third component comprising phenobarbital and belladonna levoratory alkaloids each incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer resin matrix.
Claim 3
Dependent Claim
32 words
The formulation of claim 1, wherein the concentration of belladonna levoratory alkaloids in the second component is from about 1/10 to about 1/1000 of the total concentration of sustained release medicament formulations.
Claim 4
Dependent Claim
31 words
The formulation of claim 2, wherein the concentration of belladonna levoratory alkaloids in the second component is from 1/100 to 1/300 of the total concentration of the sustained release medicament formulation.
Claim 5
Dependent Claim
31 words
The formulation of claim 1, wherein the basic pH affected controlled release matrix is selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, and hydroxy propylmethyl cellulose phthalate.
Claim 6
Dependent Claim
17 words
The formulation of claim 4, wherein the basic pH affected controlled release matrix is cellulose acetate phthalate.
Claim 7
Dependent Claim
24 words
The formulation of claim 5, wherein insoluble salts of calcium sulfate or barium sulfate are incorporated into the basic pH affected controlled release matrix.
Claim 8
Dependent Claim
86 words
A three component sustained release medicament formulation comprising: a first component comprising, phenobarbital belladonna levoratory alkaloids and ergotamine incorporated into an immediate release portion; a second component comprising belladonna levoratory alkaloids and ergotamine incorporated into a separate basic pH affected controlled release matrix; with phenobarbital, microcrystalline cellulose and calcium sulfate also incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer matrix; and a third component comprising phenobarbital and belladonna levoratory alkaloids ergotamine each incorporated into a separate control release vinyl-acetate vinyl alcohol copolymer resin matrix.
Claim 9
Dependent Claim
86 words
A three component sustained release medicament formulation comprising: a first component comprising, phenobarbital belladonna levoratory alkaloids and ergotamine incorporated into an immediate release portion; a second component comprising belladonna levoratory alkaloids and ergotamine incorporated into a separate basic pH affected controlled release matrix; with phenobarbital, microcrystalline cellulose and calcium sulfate also incorporated into a separate control release vinyl acetate-vinyl alcohol copolymer matrix; and a third component comprising phenobarbital and belladonna levoratory alkaloids ergotamine each incorporated into a separate control release vinyl-acetate vinyl alcohol copolymer resin matrix.
Claim 10
Dependent Claim
36 words
The formulation of claim 7, wherein the concentration of belladonna levoratory alkaloids and the ergotamine in the second component are each from about 1/10 to about 1/1000 of the total concentration of sustained release medicament formulation.
Claim 11
Dependent Claim
34 words
The formulation of claim 2, wherein the concentration of belladonna levoratory alkaloids and the ergotamine in the second component are from 1/100 to 1/300 of the total concentration of the sustained release medicament formulation.
Claim 12
Dependent Claim
31 words
The formulation of claim 7, wherein the basic pH affected controlled release matrix is selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, and hydroxy propylmethyl cellulose phthalate.
Claim 13
Dependent Claim
17 words
The formulation of claim 10, wherein the basic pH affected controlled release matrix is cellulose acetate phthalate.
Claim 14
Dependent Claim
24 words
The formulation of claim 11, wherein insoluble salts of calcium sulfate or barium sulfate are incorporated into the basic pH affected controlled release matrix.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-03-14 | 1980-09-13 | 1981-03-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-03-14 | 1984-09-13 | 1985-03-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-03-14 | 1988-09-13 | 1989-03-15 | $7700.00 | Window Closed / Lapsed |